{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:14:25Z","timestamp":1778901265994,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["IKNL 2015-7914"],"award-info":[{"award-number":["IKNL 2015-7914"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.euo.2024.09.006","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T16:33:44Z","timestamp":1727282024000},"page":"249-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk of progression in patients with primary T1 high grade non-muscle invasive bladder cancer \u2013 a contemporary cohort"],"prefix":"10.1016","volume":"8","author":[{"given":"Olga M.","family":"Pijpers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.C.","family":"van Hoogstraten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiaan","family":"Remmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene J.","family":"Beijert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorg R.","family":"Oddens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Alfred Witjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambertus A.","family":"Kiemeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja K.H.","family":"Aben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost L.","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.09.006_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.006_b0010","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1569-9056(06)61080-4","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"5","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.006_b0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.006_b0020","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2018.06.024","article-title":"Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations","volume":"74","author":"Klaassen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.006_b0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s12885-020-06954-7","article-title":"Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB)","volume":"20","author":"Ripping","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2024.09.006_b0030","unstructured":"US Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment. Guidance for industry. Rockville, MD: FDA; 2018."},{"key":"10.1016\/j.euo.2024.09.006_b0035","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.09.006_b0040","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.eururo.2018.12.014","article-title":"Guidelines for reporting of statistics for clinical research in urology","volume":"75","author":"Assel","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.006_b0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non\u2013muscle-invasive stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.006_b0050","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","article-title":"Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:34:38Z","timestamp":1778898878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124002165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2588931124002165"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.09.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of progression in patients with primary T1 high grade non-muscle invasive bladder cancer \u2013 a contemporary cohort","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}